Johnson & Johnson Partners with Myeloma Ireland for ‘Rooted in Resilience’ garden at Bloom 2026
Johnson & Johnson has partnered with Myeloma Ireland as lead sponsor of the gold medal-winning ‘Rooted in Resilience’ garden at Bloom 2026.
Read more
Haematology
DARZALEX® Becomes First Oncology Injectable Approved for Self-Administration in Europe
Johnson & Johnson has announced European approval for eligible multiple myeloma patients or caregivers to self-administer DARZALEX® from the fifth dose onwards.
Read more
Expanded access to CAR T-cell therapies in Ireland for adults with certain blood cancers
Gilead Sciences and Kite have announced the reimbursement of two CAR T-cell therapies in Ireland for eligible adult patients with certain relapsed or refractory blood cancers.
Read more
First CAR T Therapy for Relapsed or Refractory Adult ALL Now Reimbursed in Ireland
Gilead Sciences and Kite have confirmed that Tecartus (brexucabtagene autoleucel), the first CAR T therapy for relapsed or refractory adult B-cell precursor acute lymphoblastic leukaemia, is now reimbursed in Ireland, offering a personalised treatment option supported by pivotal ZUMA-3 trial data.
Read more